R. Kozak

发表

Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity.

T. Waldmann, S. Mirzadeh, M. Brechbiel, 1989, Cancer research.

Pharmaceuticals in the Environment: Focus on 17α-ethinyloestradiol

W. Verstraete, R. Kozak, I. D'haese, 2001 .

Cell receptor assays.

K. Zoon, D. zur Nedden, R. Kozak, 1989, Journal of pharmaceutical and biomedical analysis.

Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and imaging

Martin W. Brechbiel, M. Brechbiel, O. Gansow, 1994 .

Radioimmunotherapy of Nude Mice Bearing a Human Interleukin 2 Receptor α-expressing Lymphoma Utilizing the α-emitting Radionuclide-conjugated Monoclonal Antibody 212Bi-anti-Tac

T. Waldmann, M. Brechbiel, K. Garmestani, 1994 .

Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy.

T. Waldmann, A. M. Friedman, O. Gansow, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Radionuclide-conjugated monoclonal antibodies: a synthesis of immunology, inorganic chemistry and nuclear science

T. Waldmann, O. Gansow, R. Atcher, 1986 .

Alpha particle emitting constructs of recomblnant humanized antl-CD33 for myelold teukemlas

D. Scheinberg, O. Gansow, C. Apostolidis, 1994 .

Bismuth-212-labeled anti-Tac monoclonal antibody : a-Particle-emitting radionuclides as modalities for radioimmunotherapy ( interleukin 2 receptors / adult T-cell leukemia / diethylenetriaminepentaacetic acid

T. Waldmann, A. M. Friedman, J. Hines, 2022 .

Evaluation of dithiol chelating agents as potential adjuvants for anti-IL-2 receptor lead or bismuth alpha radioimmunotherapy.

K. Garmestani, O. Gansow, S. Jones, 1996, Nuclear medicine and biology.

Baby hamster kidney cell–derived recombinant factor VIII: a quarter century of learning and clinical experience

C. Kessler, P. Petraro, P. Mathew, 2016, Expert review of hematology.

Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.

M. Brechbiel, K. Garmestani, O. Gansow, 1994, Cancer research.

Role and Molecular Biology of the Interleukin–2-Interleukin-2 Receptor System in Health and Disease

T. Waldmann, C. Goldman, M. Tsudo, 1986 .

Selective elimination in vitro of alloresponsive T cells to human transplantation antigens by toxin or radionuclide conjugated anti-IL-2 receptor (Tac) monoclonal antibody.

T. Waldmann, I. Pastan, C. Goldman, 1990, Journal of immunology.

Antitumor effect of212bismuth-conjugated anti-IL-2R monoclonal antibody(2E4) on a IL-2 receptor positive tumor EL4J3.4

Sung-Hoon Kim, R. Kozak, B. Ahn, 1994 .

IL-2 receptors in adult T-cell leukemia: a target for immunotherapy.

T. Waldmann, C. Goldman, M. Tsudo, 1987, Haematology and blood transfusion.

Radiolabeled CHXB-2E4 is stable in vivo and is a suitable immunoconjugate for testing α-particle-emitting bismuth radionuclides in interleukin-2 receptor targeted immunotherapy

T. Waldmann, M. Brechbiel, K. Garmestani, 1994 .

Lymphocyte proliferation induced by autologous cells. XV. Relationships between the human autologous mixed lymphocyte reaction stimulated by non-T and activated T cells.

M. Weksler, R. Kozak, R. Schwab, 1985, Human immunology.

The autologous mixed-lymphocyte reaction.

M. Weksler, C. Moody, R. Kozak, 1981, Advances in immunology.

Lymphocyte transformation induced by autologous cells. V. generation of immunologic memory and specificity during the autologous mixed lymphocyte reaction

R. Kozak, M. Weksler, 1977, The Journal of experimental medicine.

Lymphocyte transformation induced by autologous cells. XII. Quantitative and qualitative differences between human autologous and allogeneic reactive T lymphocytes.

L. Staiano‐Coico, M. Weksler, C. Moody, 1982, Journal of immunology.

Immunological studies of aging. Decreased production of and response to T cell growth factor by lymphocytes from aged humans.

M. Weksler, S. Gillis, R. Kozak, 1981, The Journal of clinical investigation.

Expression and function of insulin-like growth factor receptors on anti-CD3-activated human T lymphocytes.

R. Kozak, L. A. Jones, E. Johnson, 1992, Journal of immunology.

Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.

T. Waldmann, C. Goldman, M. Tsudo, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Contribution of a p75 interleukin 2 binding peptide to a high-affinity interleukin 2 receptor complex.

T. Waldmann, C. Goldman, M. Tsudo, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Type I and II insulin-like growth factor receptors on human phytohemagglutinin-activated T lymphocytes.

T. Waldmann, M. Rechler, S. Nissley, 1987, Cellular immunology.

Policy considerations for originator and similar biotherapeutic products

G. Grampp, R. Kozak, Thomas Schreitmueller, 2016 .

Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.

D. Scheinberg, M. Brechbiel, M. McDevitt, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells.

T. Waldmann, I. Pastan, M. Willingham, 1990, Journal of immunology.

Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.

R. Kozak, P. Stadler, C. Golker, 1996, Developments in biological standardization.